
# RealRate

## PHARMACEUTICAL 2018

# ARDELYX INC. Rank 144 of 349







#### PHARMACEUTICAL 2018

### ARDELYX INC. Rank 144 of 349



The relative strengths and weaknesses of ARDELYX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARDELYX INC. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 85% points. The greatest weakness of ARDELYX INC. is the variable Research and Development, reducing the Economic Capital Ratio by 136% points.

The company's Economic Capital Ratio, given in the ranking table, is -122%, being 155% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	149,712
Cost of Goods Sold	8,400
Intangible Assets	0
Liabilities, Current	17,871
Liabilities, Non-Current	720
Other Assets	159
Other Compr. Net Income	24
Other Expenses	1,179
Other Liabilities	0
Other Net Income	1,955
Property and Equipment	8,032
Research and Development	75,484
Revenues	42,000
Selling, General and Administrative Expense	23,231

Output Variable	Value in 1000 USD
Assets	157,903
Liabilities	18,591
Expenses	108,294
Stockholders Equity	139,312
Net Income	-64,339
Comprehensive Net Income	-64,327
Economic Capital Ratio	-122%